Neuroimaging features of antiphospholipid antibody-related stroke compared with atrial fibrillation-related stroke
Wookjin Yang, Dong-Wan Kang, Jeong-Min Kim, Keun-Hwa Jung, Seung-Hoon Lee, Wookjin Yang, Dong-Wan Kang, Jeong-Min Kim, Keun-Hwa Jung, Seung-Hoon Lee
Abstract
Recognizing the lesion pattern of antiphospholipid antibody-related stroke (aPL-stroke) may contribute to establishing the cause in patients with cryptogenic stroke. We aimed to describe the neuroimaging features of aPL-stroke compared with atrial fibrillation-related stroke (AF-stroke), a major hidden cause of cryptogenic stroke. Using a prospective stroke registry, we identified consecutive aPL- and AF-stroke patients without other potential causes of stroke. Neuroimaging features based on diffusion-weighted imaging and angiographic findings at admission were compared. A total of 56 and 333 patients were included in the aPL- and AF-stroke groups, respectively. aPL-stroke patients more often presented with single small lesions (aPL-stroke, 30.4% vs. AF-stroke, 7.5%, p < 0.001), while the predominant pattern in AF-stroke patients was large territorial lesions (26.8% vs. 56.5%, p < 0.001). aPL-stroke patients had smaller infarct volume (1.58 mL [0.45; 9.41] vs. 11.32 mL [2.82; 33.08], p < 0.001) and less experience of relevant artery occlusion (17.9% vs. 54.7%, p < 0.001). The proportion of multi-territory lesions, an embolic pattern, was similar between the two groups (28.6% vs. 22.8%, p = 0.44). In comparison only including patients with multi-territory lesions as well, aPL-stroke patients showed small lesion dominance and smaller infarct volume. Multivariate analyses showed independent associations between mild neuroimaging features (small lesion prevalence, smaller infarct volume, and absence of relevant artery occlusion) and aPL-stroke. Patterns of small lesion prevalence, small infarct volume, and absence of relevant artery occlusion were suggestive of aPL-stroke rather than AF-stroke. Cryptogenic stroke patients with such neuroimaging features may benefit from aPL testing for a precise diagnosis.
Conflict of interest statement
The authors declare no competing interests.
© 2022. The Author(s).
Figures
References
- The Antiphospholipid Antibodies in Stroke Study Group Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke. 1990;21:1268–1273. doi: 10.1161/01.STR.21.9.1268.
- Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990;40:1181–1189. doi: 10.1212/WNL.40.8.1181.
- Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Antiphospholipid antibodies: Findings at arteriography. AJNR Am. J. Neuroradiol. 1998;19:611–616.
- Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am. J. Roentgenol. 1996;167:1573–1578. doi: 10.2214/ajr.167.6.8956600.
- Lu Y, et al. Insertable cardiac monitors for detection of atrial fibrillation after cryptogenic stroke: A meta-analysis. Neurol. Sci. 2021;42:4139–4148. doi: 10.1007/s10072-021-05104-6.
- Yang W, et al. Current status and role of antiphospholipid antibody testing in cryptogenic stroke. Eur. J. Neurol. 2022;29:753–760. doi: 10.1111/ene.15191.
- Pengo V, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365–1371. doi: 10.1182/blood-2018-04-848333.
- Ordi-Ros J, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann. Intern. Med. 2019;171:685. doi: 10.7326/M19-0291.
- Woller SC, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: A randomized trial. Blood Adv. 2022;6:1661–1670. doi: 10.1182/bloodadvances.2021005808.
- Cheng C, Cheng GY, Denas G, Pengo V. Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment A systematic review. Blood Rev. 2021;48:100788. doi: 10.1016/j.blre.2020.100788.
- Corban MT, et al. Antiphospholipid syndrome: Role of vascular endothelial cells and implications for risk stratification and targeted therapeutics. J. Am. Coll. Cardiol. 2017;69:2317–2330. doi: 10.1016/j.jacc.2017.02.058.
- Ricarte IF, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus. 2018;27:1404–1414. doi: 10.1177/0961203318776110.
- Arboix A, Alio J. Cardioembolic stroke: Clinical features, specific cardiac disorders and prognosis. Curr. Cardiol. Rev. 2010;6:150–161. doi: 10.2174/157340310791658730.
- Nalli C, Andreoli L, Casu C, Tincani A. Management of recurrent thrombosis in antiphospholipid syndrome. Curr. Rheumatol. Rep. 2014;16:405. doi: 10.1007/s11926-013-0405-4.
- Jung DK, Devuyst G, Maeder P, Bogousslavsky J. Atrial fibrillation with small subcortical infarcts. J. Neurol. Neurosurg. Psychiatry. 2001;70:344–349. doi: 10.1136/jnnp.70.3.344.
- Seifert T, et al. Acute small subcortical infarctions on diffusion weighted MRI: Clinical presentation and aetiology. J. Neurol. Neurosurg. Psychiatry. 2005;76:1520–1524. doi: 10.1136/jnnp.2005.063594.
- Devreese KMJ, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J. Thromb. Haemost. 2020;18:2828–2839. doi: 10.1111/jth.15047.
- Fontana P, Poncet A, Lindhoff-Last E, de Moerloose P, Devreese KM. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection of anticardiolipin and anti-beta2 glycoprotein-1 antibodies. J. Thromb. Haemost. 2014;12:2034–2037. doi: 10.1111/jth.12732.
- de Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J. Thromb. Haemost. 2010;8:1540–1546. doi: 10.1111/j.1538-7836.2010.03857.x.
- Kim BJ, et al. Imaging characteristics of ischemic strokes related to patent foramen ovale. Stroke. 2013;44:3350–3356. doi: 10.1161/STROKEAHA.113.002459.
- Rovira A, Grive E, Rovira A, Alvarez-Sabin J. Distribution territories and causative mechanisms of ischemic stroke. Eur. Radiol. 2005;15:416–426. doi: 10.1007/s00330-004-2633-5.
- Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J. Thromb. Haemost. 2006;4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x.
Source: PubMed